

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/565	A1	(11) International Publication Number: WO 98/56386 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/EP98/03392 (22) International Filing Date: 5 June 1998 (05.06.98) (30) Priority Data: MI97A001372 11 June 1997 (11.06.97) IT (71) Applicant (for all designated States except US): SUNNIMEX LIMITED [GB/GB]; 66 Wigmore Street, London W1H 0HQ (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): CAMPONOVO, Tiziano [IT/GB]; 66 Wigmore Street, London W1H 0HQ (GB). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A MEDICAMENT USEFUL FOR THE TREATMENT OF POST-MENOPAUSAL SYNDROME AND OSTEOPOROSIS, AND FOR REDUCING FAT MASS AND INCREASING LEAN BODY MASS (57) Abstract The use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for the treatment of post-menopausal syndrome, for the treatment and prevention of osteoporosis, and inducing a decrease in the fat mass and an increase in the lean body mass, in menopausal and in both sexes in ageing.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A MEDICAMENT USEFUL FOR THE TREATMENT OF POST-MENOPAUSAL
SYNDROME AND OSTEOPOROSIS, AND FOR REDUCING FAT MASS AND
INCREASING LEAN BODY MASS

Summary of invention

The present invention relates to the use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for the treatment of deficiencies of
5 delta 5-androsten hormones. More particularly, androst-5-ene-3 β ,17 β -diol is used in the treatment of post-menopausal syndrome, in the treatment and prevention of osteoporosis, and for inducing a decrease in fat mass and an increase in lean body mass.

10 Technological background

Androst-5-ene-3 β ,17 β -diol is a 19 carbon atoms steroid produced physiologically by the human adrenal gland. The mean blood concentrations of this hormone are usually of about 4.5 nanomols (1.3 ng/ml) per litre. The
15 blood values of this hormone decrease in menopausal woman (Cummings AC, et al., J. Clin. Endocrinol. Metab. 54:1069-71, 1982), in obesity (Tchernof A, et al.. Metab. 44:517-19, 1995) and in ageing in both sexes (Parker LN. Academic. Press, New York, 615 pp, 1989).
20 Androst-5-ene-3 β ,17 β -diol is known to be used as an anabolic agent, i.e. it promotes an increase in muscle bulk.

Androstenediol is produced by the adrenal gland through hydroxylation of DHEA (dehydroepiandrosterone).
25 The metabolic pathway of androstenediol is complex. This hormone is in part hydroxylated to both α and β androstenediols. It should be stressed that DHEA,

androstenediol and its 7 β -hydroxylated derivative are immune stimulators (Padgett DA. J. Immunol. 153:1544-52, 1994). This hormone is converted in peripheral tissues to androgens (mainly androstenedione and, to a lesser extent, testosterone) and estrogens (mainly estrone and, to a lesser extent, estradiol) by the action of the enzymes 17 β dehydrogenase, 3 β -dehydrogenase, 5- Δ 4 isomerase and 5 α reductase and aromatase, mostly contained in the fat mass (Feher T. Endocrinologie. 80:173-180, 1982; Deslyper JP, et al.. J. Clin. Endocrinol. Metab. 61:564-570, 1985; Kilinger DW. Ann. NY Acad. Sci. 595:199-214, 1990).

The increase in fat mass and the reduction in the lean body mass is a metabolic alteration occurring with particular frequency in post-menopausal women (Aloia JF, et al., Am. J. Obstet Gynecol. 172:896-900, 1995) and in both sexes in ageing.

During post-menopause woman spontaneously tends to gain weight as a consequence of an increase in fat mass, whereas her strength decreases as the muscle bulk is reduced (Aloia JF, et al... Am. J. Obstet Gynecol. 172:896-900, 1995; Morales AJ, et al... J. Clin. Endocrinol. Metab. 78:1360-67, 1994). These phenomena are associated to vasomotor disturbances, osteoporosis, changes in sexual behaviour, loss of libido, reduced sense of well-being, physiological and psychic fatigue. The traditional hormone replacement therapy, which has been used for a long time for the prevention and treatment of menopause, does not increase androstenediol blood levels nor modifies the fat mass/lean body mass ratio, which shifts towards fat

mass. The estrogen treatment often does not restore sexuality, libido and well-being.

Disclosure of the invention

It has now surprisingly been found that the
5 administration of androst-5-ene-3 β ,17 β -diol in the
deficiencies of delta 5-androsten hormones reduces and
eliminates menopausal disturbances, counteracts bone
loss, reduces the fat mass, promoting an increase in the
lean body mass until restoring a suitable balance
10 thereof. Contrary to estrogens, androst-5-ene-3 β ,17 β -
diol does not stimulate the growth of endometrium;
therefore it has not to be combined with progestins.

Therefore it is an object of the present invention
the use of androst-5-ene-3 β ,17 β -diol for the preparation
15 of a medicament useful for the treatment of deficiencies
of the above mentioned hormones.

More specifically, it is an object of the present
invention the use of androst-5-ene-3 β ,17 β -diol for the
preparation of a medicament useful for the treatment of
20 post-menopausal syndrome and osteoporosis, and for
inducing a decrease in fat mass and an increase in lean
body mass in menopausal women.

It is a further object of the present invention the
use of androst-5-ene-3 β ,17 β -diol for the preparation of
25 a medicament useful for inducing a decrease in fat mass
and an increase in lean body mass in ageing humans.

It is still a further object of the invention a
pharmaceutical composition containing an effective
amount of androst-5-ene-3 β ,17 β -diol as active ingredient
30 in admixture with pharmaceutically acceptable excipients
and carriers, more particularly a composition suitable

for the oral administration, as well as a composition providing the administration of continuous doses of androst-5-ene-3 β ,17 β -diol by the transdermal route.

Advantageously, the use of androst-5-ene-3 β ,17 β -diol according to the present invention involves a very slight androgenic activity and the effective amounts of the active ingredient are very low.

Detailed disclosure of the invention

According to the present invention, the medicament containing androst-5-ene-3 β ,17 β -diol is useful for the treatment of deficiencies of delta 5-androsten hormones; produced by the adrenal gland:

- 1) in the treatment of physio-pathological conditions characterized by asthenia, fatigue, loss of libido, decrease in strength and well-being, as occurring in post-menopause and, in both sexes, in ageing;
- 2) in the prevention and treatment of menopausal syndrome;
- 3) in the prevention and treatment of post-menopausal osteoporosis;
- 4) for restoring a suitable fat mass / lean body mass relationship, similar to that of the healthy human;
- 5) in the treatment of the conditions related to a decrease in androstenediol production by the adrenal gland, with a corresponding decrease in blood concentration, such as in chronic, infectious and psychic diseases characterized by hypercortisolism, any excessive action of which is counteracted by androst-5-ene-3 β ,17 β -diol;
- 6) in the prevention of metabolic and psychophysical alterations occurring during menopause and ageing;

5

7) finally, in the treatment of men after the 50th year to modify climacteric symptoms, to reduce fat mass and to increase muscle strength.

Androst-5-ene-3 β ,17 β -diol is a substantially harmless product present in the body as a natural component, so that it involves no toxicity problems.

Androst-5-ene-3 β ,17 β -diol can be administered together with other active ingredients or directly combined therewith, in post-menopause and in ageing. In particular, it can be administered together with estrogens in the prevention and in the treatment of menopause symptoms and disturbances, without need for combining it with progestins.

According to the invention, suitable doses of androst-5-ene-3 β ,17 β -diol range from 5 to 30 mg/day per os.

According to the present invention, the administration of androstenediol in post-menopausal women effectively counteracts menopausal symptoms and decreases fat mass, contrary to estrogens which do not affect it, thus suggesting a regulating activity of androstenediol on fatty tissue. This action is not likely to be exerted by dehydroepiandrosterone (DHEA), another C19 steroid precursor of androstenediol, having, like the latter, a protein anabolic action. In fact, the treatment of obese patients with DHEA does not seem to cause a loss of fat mass (Usiskin KS, et al.. Int. J. Obes. 14:457-463, 1990). Khaw KT, et al.. (Ann. Epidemiol. 2:675-682, 1992) reported that in man no correlations exist between blood concentrations of Δ 4-androstenedione (another weak androgen) and testosterone

6

and fat distribution, when results were corrected per age and body mass index, thus excluding any cause-effect relationship between these two hormones and the fat distribution in man. A balancing action of androstenediol on fat mass is, therefore, quite unexpected, contrary to its protein anabolic action.

A further advantage of the present invention is that the active ingredient is substantially non toxic.

In the following, some data relating to the pharmacological trials are reported.

Pharmacological trials

Studies were carried out on 14 52-54 years old women. All women had been in amenorrhea for about 6-12 months and had low values of estradiol. Seven subjects were treated with a therapy comprising: conjugated estrogens 0.625 mg/day for 28 days plus medroxyprogesterone acetate 10 mg/day for 11 days with a one week suspension, for 8 overall cycles. The other seven subjects were administered with androst-5-ene-3 β ,17 β -diol. Fat mass, lean body mass, bone mass, body weight were evaluated by means of DEXA HOLOGIC. In the following there are reported the mean percent values of cholesterol, HDL cholesterol, fat mass and lean body mass of the two groups of subjects before treatment and after treatments with estro-progestins and with androst-5-ene-3 β ,17 β -diol 10 mg/day.

		Total cholesterol	HDL cholesterol	Fat mass	Lean body mass
Mean values in estro- progestin therapy	Before	214 ± 30 mg/100 ml	54 ± 12 mg/100 ml	31.4%	61.8%
	After	222 ± 20 mg/100 ml	58 ± 10 mg/100 ml	33.4%	59.6%
Mean values in andro- stenediol therapy 10 mg/day	Before	224 ± 18 mg/100 ml	56 ± 14 mg/100 ml	32.2%	60.8%
	After	211 ± 23 mg/100 ml	54 ± 12 mg/100 ml	28.8%	65%

The differences between basal values and values after treatment were significant both for fat mass ($p < 0.01$) and for lean body mass ($p < 0.01$) in patients treated with androst-5-ene-3 β ,17 β -diol. Total
5 cholesterol was found to have a tendency to decrease, whereas HDL cholesterol remained unchanged.

In patients who received treatment with estrogen-progestins basal values were not different from post-treatment values. No significant differences in bone
10 mass of the subjects treated with the two different therapies were found, in that in both cases bone mass remained stable or tended to increase. On the contrary, menopausal-related symptoms, such as flushing, perspiration, irritability, depression were absent in
15 both the studied groups; the group treated with androst-5-ene-3 β ,17 β -diol, however, being more sthenic and having a better sense of well-being.

These data suggest that estrogen-progestins, administered during post-menopause, are not capable of
20 restoring the fat mass/lean body mass ratio. On the contrary, androst-5-ene-3 β ,17 β -diol significantly increased lean body mass and reduced as much significantly fat mass. The weight of the patients and the bone mass at the end of the treatment (after 8
25 months) were substantially superimposable. However, the fat mass/lean body mass ratio shifted towards lean body mass.

The therapy with androst-5-ene-3 β ,17 β -diol protracted for 8 months, induced no significant changes
30 in total cholesterol, LDL cholesterol, triglycerids and glycemia. Furthermore, no significant increases in

circulating androgens were observed: free testosterone and androstenedione only showed a slight tendency to increase, such an increase, however, being not significant at the used doses. Moreover, an improvement
5 in sexual behaviour and well-being was observed in all the treated women, together with a reduction of asthenia in patients in which the symptom had been present.

As far as the industrial applicability is concerned, the medicaments according to the present
10 invention are formulated as pharmaceutical compositions. Said compositions, which are a further object of the invention, will be prepared according to conventional methods known to those skilled in the art. Said methods are, for example, described in "Remington's
15 Pharmaceutical Sciences Handbook", Mack Publishing Company, New York, U.S.A.

The compositions according to the invention contain an effective amount of active ingredient in admixture with pharmaceutically acceptable carriers and
20 excipients. More specifically, the compositions will be in the form of unitary dosages suitable for the administration of up to 30 mg of androst-5-ene-3 β ,17 β -diol, preferably 10 mg, daily. The dosage units can be single or subdivided in the therapeutical daily dose.

25 Examples of pharmaceutical compositions include tablets, capsules, pills, solutions, syrups, injectable forms, topical forms such as creams or ointments, or transdermal formulations.

Transdermal formulations are particularly
30 preferred, and they are a further object of the invention. Such formulations have a good compliance and,

10

more interestingly, are particularly suitable for long-term treatments, also considering the active principle half-life. These formulations provide an effective, homogeneous, cutaneous absorption, and they cause no blood peaks, as often occurs in topical treatments with conventional formulations.

The transdermal formulations according to the invention consist of a solution of androst-5-ene-3 β ,17 β -diol in a mixture of an alcohol (preferably absolute ethanol) and a glycol (preferably propylene glycol), added with one or more polymeric compounds, such as cellulose derivatives (for example ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose), polyacrylic and/or polymethacrylic acid esters and the like, and further containing the conventional excipients and/or plasticizers.

Said formulations will be contained in containers equipped with a dispenser to apply the correct dose of the formulation to the skin. After evaporation of the solvent, the film remaining on the skin releases the active principle in the space of 24 hr and can subsequently be removed by the usual detergents.

The following examples further illustrate the invention.

25 EXAMPLE 1

Compound	% w/w
Androst-5-ene-3 β ,17 β -diol	1.000
Ethyl cellulose	7.000
Propylene glycol	2.000
30 Stearic acid	4.000
Hydroxypropyl cellulose	1.000

11

Colloidal silica 1.000
Absolute ethanol q.s. to 100

5 The solution is distributed in an aluminium container coated internally with epoxy phenolic resins, equipped with a dispenser.

The formulation was characterized by an in vitro dissolution test (Dissolution test USP) and the release kinetics of the active principle during an 8 hr time was evaluated (see figure).

10 EXAMPLE 2

Compound	% w/w
Androst-5-ene-3 β ,17 β -diol	0.500
Methacrylic acid esters	5.000
Povidone	2.000
15 Propylene glycol	2.000
Stearic acid	4.000
Hydroxypropyl cellulose	1.000
Colloidal silica	1.000
Absolute ethanol	q.s. to 100

20 The solution is distributed in an aluminium container coated internally with epoxy phenolic resins, equipped with a dispenser.

EXAMPLE 3

Compound	% w/w
Androst-5-ene-3 β ,17 β -diol	1.000
Methacrylic acid esters	5.000
Propylene glycol	2.000
Cetyl alcohol	4.000
30 Hydroxymethyl cellulose	1.000
Colloidal silica	1.000

12

Absolute ethanol

q.s. to 100

The solution is distributed in an aluminium container coated internally with epoxy phenolic resins, equipped with a dispenser.

CLAIMS

1. The use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for the treatment of deficiencies of delta 5-androsten hormones.
2. The use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for controlling the post-menopausal syndrome.
3. The use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for controlling osteoporosis.
4. The use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for inducing a decrease in fat mass and an increase in the lean body mass in menopausal women.
5. The use as claimed in claim 2, wherein androst-5-ene-3 β ,17 β -diol is in combination with other active principles.
6. The use as claimed in claim 5, wherein said other active principles are estrogens and/or estro-progestins.
7. The use of androst-5-ene-3 β ,17 β -diol for the preparation of a medicament useful for inducing a decrease in fat mass and an increase in the lean body mass in an ageing humans.
8. Pharmaceutical composition containing an effective amount of androst-5-ene-3 β ,17 β -diol as active ingredient in admixture with pharmaceutically acceptable excipients and carriers.
9. Pharmaceutical composition as claimed in claim 6, containing an amount of active ingredient from 5 to 30 mg for a daily administration.

14


10. Pharmaceutical compositions as claimed in claim 8 or 9 for the transdermal administration.

11. Transdermal formulations as claimed in claim 10, consisting of a solution of androst-5-ene-3 β ,17 β -diol in
5 a mixture of an alcohol and a glycol, added with one or more polymeric compounds, selected from polyacrylic and/or polymethacrylic acid esters and the like, and further containing the conventional excipients and/or plasticizers.

10 12. Transdermal formulations as claimed in claim 11, wherein the alcohol is absolute ethanol, the glycol is propylene glycol and the cellulose derivatives are selected from ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose.

15 13. Composition as claimed in claim 8 or 9 for the oral administration.

Androst-5-ene-3 β ,17 β -diol in vitro release kinetics



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03392

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/565

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 206 008 A (LOTIA) 27 April 1993 see column 12, line 23 - line 32 see column 12, line 48 - line 52 see claims 2,10 see column 14, line 31 - line 35 --- -/--</p>	8-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Date of mailing of the international search report

09/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Theuns, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/03392

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M. SHIRAKI ET AL.: "The effect of estrogen and, sex-steroids and thyroid hormone preparation on bone mineral density in senile osteoporosis -- a comparative study of the effect of 1 alpha-hydroxycholecalciferol (1 alpha-OHD3) on senile osteoporosis" DIALOG(R) FILE 155: MEDLINE(R), ACCESSION NUMBER 07422603: NIPPON NAIBUNPI GAKKAI ZASSHI, vol. 67, no. 2, 20 February 1991, pages 84-95, XP002082222 see abstract ---	1-13
X	S.YOSHIMOTO ET AL.: "Clinical effects of metharmon F for postmenopausal women with climacteric symptoms: its relationship with serum level of hormones" DIALOG(R) FILE 155: MEDLINE(R), ACCESSION NUMBER 04630234: HORUMON TO RINSHO, vol. 31, no. 8, August 1983, pages 815-822, XP002082223 see abstract ---	1-13
X	EP 0 424 954 A (NIPPON ZOKI PHARMACEUTICAL CO. LTD.) 2 May 1991 see the whole document see page 2, line 44 see page 6, line 21 - line 41 see page 5; table 2 see page 6, line 14 - line 16 see claim 7 ---	1-13
X	US 5 387 583 A (LORIA) 7 February 1995 see column 19, line 65 - column 20, line 26 see claims 1-7 ---	8-13
X	US 5 277 907 A (LORIA) 11 January 1994 see column 4, line 16 - line 24 see column 4, line 29 - line 33 see column 13, line 25 - line 43 see column 13, line 52 - column 14, line 3 see column 14, line 29 - line 68 ---	8-13
X	US 5 478 566 A (LORIA) 26 December 1995 see column 4, line 16 - line 22 see column 4, line 28 - line 32 see examples 5,6 ---	8-13
X,P	US 5 656 286 A (MIRANDA ET AL.) 12 August 1997 see column 12, line 41 ---	8-13
-/--		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 98/03392

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 40086 A (NOVEN PHARMACEUTICALS, INC.) 19 December 1996 see page 25, line 1 ---	8-13
X,P	US 5 641 768 A (LORIA) 24 June 1997 see column 4, line 56 - line 62 see column 5, line 1 - line 4 see column 13, line 65 - column 14, line 3 see column 14, line 57 - column 15, line 24 see claims 1-6 ---	8-13
X	US 5 183 815 A (SAARI ET AL.) 2 February 1993 see column 4, line 49 - line 61 see column 11, line 17 - column 12 see claims 1,2 ---	1-13
A	M.E.WEKSLE: "Hormone replacement for men" BRITISH MEDICAL JOURNAL, vol. 312, no. 7035, 6 April 1996, pages 859-860, XP002082224 see the whole document ---	1-13
X	C.E.BIRD ET AL.: "Delta5-androstenediol: kinetics of metabolism and binding to plasma proteins in normal post-menopausal women" ACTA ENDOCRINOL., vol. 99, no. 2, February 1982, pages 309-313, XP002082225 see the whole document ---	1-13
X	M.J.REED ET AL.: "THE EFFECTS OF ANDROGENS AND CORTISOL ON THE IN VIVO METABOLISM OF OESTRADIOL" J.STEROID BIOCHEM., vol. 30, no. 1-6, 1988, pages 589-492, XP002082226 see abstract ---	1-13
X	S.BUDAVARI ET AL., EDS.: "THE MERCK INDEX, 12th Edition" 1996, MERCK & CO., INC., WHITEHOUSE STATION, NJ XP002082227 see page 107 -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03392

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5206008	A	27-04-1993	AU 2265092 A EP 0637203 A WO 9320696 A US 5277907 A US 5461042 A US 5641768 A	18-11-1993 08-02-1995 28-10-1993 11-01-1994 24-10-1995 24-06-1997
EP 0424954	A	02-05-1991	DE 69008476 D DE 69008476 T ES 2055845 T JP 3209328 A US 5116828 A	01-06-1994 01-09-1994 01-09-1994 12-09-1991 26-05-1992
US 5387583	A	07-02-1995	WO 9423722 A	27-10-1994
US 5277907	A	11-01-1994	US 5206008 A US 5461042 A US 5641768 A AU 2265092 A EP 0637203 A WO 9320696 A	27-04-1993 24-10-1995 24-06-1997 18-11-1993 08-02-1995 28-10-1993
US 5478566	A	26-12-1995	NONE	
US 5656286	A	12-08-1997	US 5474783 A US 5300291 A US 4994267 A US 4814168 A AU 1521295 A BR 9506470 A CA 2180530 A CN 1143318 A EP 0737066 A FI 962770 A HU 74913 A JP 9511987 T NO 962833 A NZ 278769 A SG 49331 A WO 9518603 A	12-12-1995 05-04-1994 19-02-1991 21-03-1989 01-08-1995 07-10-1997 13-07-1995 19-02-1997 16-10-1996 29-08-1996 28-03-1997 02-12-1997 15-08-1996 27-04-1998 18-05-1998 13-07-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03392

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5656286 A		ZA 9500108 A	25-03-1996
		AU 670033 B	04-07-1996
		AU 2268992 A	25-01-1993
		BR 9206208 A	22-11-1994
		CA 2110914 A	07-01-1993
		EP 0591432 A	13-04-1994
		FI 935833 A	23-12-1993
		JP 6510279 T	17-11-1994
		MX 9203648 A	31-01-1995
		NO 934523 A	10-02-1994
		SG 49164 A	18-05-1998
		WO 9300058 A	07-01-1993
		US 5686099 A	11-11-1997
		US 5719197 A	17-02-1998
		AT 122240 T	15-05-1995
		AU 632534 B	07-01-1993
		AU 5034990 A	13-08-1990
		CA 2044132 A, C	12-07-1990
		DE 69019175 D	14-06-1995
		DE 69019175 T	18-01-1996
		DK 379045 T	09-10-1995
		EP 0379045 A	25-07-1990
		EP 0453505 A	30-10-1991
		EP 0634179 A	18-01-1995
		ES 2071683 T	01-07-1995
		IE 69048 B	07-08-1996
		JP 7093939 B	11-10-1995
		JP 4502719 T	21-05-1992
		NL 9020159 A	02-01-1991
		PT 92830 A, B	31-07-1990
		US 5405486 A	11-04-1995
		WO 9007940 A	26-07-1990
		US 5032207 A	16-07-1991
		US 5656285 A	12-08-1997
WO 9640086 A	19-12-1996	US 5719197 A	17-02-1998
		AU 6029096 A	30-12-1996
US 5641768 A	24-06-1997	US 5461042 A	24-10-1995
		US 5277907 A	11-01-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03392

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5641768 A		AU 2265092 A EP 0637203 A WO 9320696 A US 5206008 A	18-11-1993 08-02-1995 28-10-1993 27-04-1993
US 5183815 A	02-02-1993	CA 2059421 A EP 0496520 A JP 4352795 A JP 7035395 B	23-07-1992 29-07-1992 07-12-1992 19-04-1995